Announcing IndieBio SF’s Next Wave – VC-Founder Meetings (June 17 to 21) Learn More

The SOSV Human Health 100 is an annual list that presents the top companies in the SOSV portfolio. They range from unicorns making a huge impact to pre-seed startups emerging from SOSV programs.

$6.67B

Aggregate Value

16

Countries

$1.43B

Total Raised

35%

Female Founders

$99M

SOSV Invested

70%

PhD Founders


SOSV Human Health 100

SOSV is committed to building deep tech startups focused on human and planetary health. Each year we produce the Human Health 100 to showcase our most exciting companies in the health category. We do the same with in the climate with our annual SOSV Climate Tech 100, which we publish in April.

We published the first SOSV Health Tech 100 in February 2022 in order to showcase our top health-related companies across our HAX and IndieBio startup development programs. The list also underscores SOSV’s strong performance on venture leaderboards for health investing, including strong rankings on PitchBook’s leaderboards for Healthcare devices & supplies, women’s health, pharma and biotech. 

At SOSV, our vantage point for health is informed by living at the deep tech intersection represented by our startup development programs HAX, IndieBio and Orbit—the Shibuya Crossing of hardware, genetics, and frontier markets.

PO BRONSON
General Partner, IndieBio

From SOSV’s standpoint, each company on the Human Health 100 represents a unique window into the very rapid advances taking place in fields as varied as cancer therapeutics, CRISPR platforms, various applications of AI, assistive robotics, and remote healthcare, to name a few. As SOSV general partner Po Bronson has argued, scientific and computational breakthroughs are seeding new products and startups at a breakneck pace even as the need for more cost-effective and scalable healthcare has never been more apparent.

For the 2024 edition of the Human Health 100, there are 16 new companies, which we detail in this post announcing the list. The aggregate valuation of the companies is $6.67 billion (up 3% from $6.47B in 2023), and all told the firms have raised $1.43 billion (up 1% from $1.42B in 2023). SOSV, which invests starting at pre-seed and continues through later stages, has invested $99 million (up 3% from $96M in 2023). Like all venture categories in the past year, health has slowed down considerably.

As with the SOSV Climate Tech 100, the diversity and sophistication of our health companies and founders is striking. 35% of the companies have a woman co-founder. The companies are located in 16 countries. 70% of the startups have at least one PhD co-founder. A  total of 52 companies graduated from the biology-centric IndieBio while another 38 hail from hard-tech focused HAX program and five from the SOSV Consortium.

You can read more about this year’s list here or review the Health 100 below.

The 2024 Human Health 100  

SOSV’s Human Health Ecosystem

Sign up for SOSV’s monthly email updates

Get the latest news from SOSV and the programs in their monthly updates on human health and other topics.

Sign Up for email updates

Apply to the HAX and IndieBio programs

Join the many health tech companies in SOSV’s programs. Applications are open year round for HAX (Newark, Shenzhen) and IndieBio (NYC and San Francisco).

Apply to HAX

Apply to IndieBio

Work in Human Health

SOSV’s health tech companies are hiring. Research job openings and join the Talent Network to get alerts on new openings.

Browse companies and roles

Join Talent Network